Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Previous studies in Parkinson's Disease (PD) models have shown promise with the use of recombinant adeno-associated virus serotype-2 (rAAV2)-neurturin (NRTN) [AAV2-NRTN] providing neuroprotection and behavioral improvements in preclinical models which subsequently resulted in several clinical studies in patients with PD.
|
31678350 |
2020 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Three growth factors, glial cell-line derived neurotrophic factor (GDNF), neurturin (NRTN) and platelet-derived growth factor (PDGF-BB) have been tested in clinical trials in Parkinson's disease (PD) during the past 20 years.
|
30947516 |
2019 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Glial cell line-derived neurotrophic factor (GDNF) and its related neurturin (NRTN) can protect DA neurons in the neurotoxin but not α-synuclein animal models of PD, it failed in the clinical trials.
|
29959908 |
2018 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Neurturin (NRTN) provides trophic support to neurons and is considered a therapeutic agent for neurodegenerative diseases, such as Parkinson's disease.
|
29414779 |
2018 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Contrariwise, very limited success was obtained in clinical studies, where glial cell line-derived neurotrophic factor and neurturin were the neurotrophic factors of choice for Parkinson's disease therapy.
|
27928963 |
2017 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The structural effect of neurturin (NRTN) on the nigrostriatal dopaminergic system in animals remains unknown, although NRTN has been shown to be effective in Parkinson's disease animal models.
|
29176874 |
2017 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Long-Term Safety of Patients with Parkinson's Disease Receiving rAAV2-Neurturin (CERE-120) Gene Transfer.
|
26711317 |
2016 |
Parkinson Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Developing therapeutically more efficient Neurturin variants for treatment of Parkinson's disease.
|
27425888 |
2016 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
In particular, studies employing glial cell line-derived neurotrophic factor (GDNF) and its family member neurturin (NRTN), as well as the recently described cerebral dopamine neurotrophic factor (CDNF) and the mesencephalic astrocyte-derived neurotrophic factor (MANF) have shown positive results in protecting and repairing dopaminergic neurons in various models of PD.
|
26616211 |
2016 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
As a scientist who has journeyed these events from the beginning and participated in many of the decisions that navigated this field, I consider it important for the movement disorder scientific community to reflect on the evolution of thought and to participate in the dialog over whether the investments were worthwhile.The most studied group of trophic factor for PD is the glial cell derived family of ligands, of which glial cell derived neurotrophic factor (GDNF) and neurturin are members, and are the best studied.
|
26611606 |
2016 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, open-label studies with GDNF as well as a study with NRTN showed clinical improvement, particularly in patients with early-stage PD.
|
26176331 |
2015 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We performed a 15- to 24-month, multicenter, double-blind trial in patients with advanced Parkinson disease (PD) who were randomly assigned to receive bilateral AAV2-neurturin injected bilaterally into the substantia nigra (2.0 × 10(11) vector genomes) and putamen (1.0 × 10(12) vector genomes) or sham surgery.
|
26061140 |
2015 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Three gene transfer paradigms for Parkinson's disease have been explored: converting L-dopa into dopamine through AADC gene delivery in the putamen; synthesizing GABA through GAD gene delivery in the overactive subthalamic nucleus and providing neurotrophic support through neurturin gene delivery in the nigro-striatal pathway.
|
23331189 |
2013 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Gene therapy has emerged as a potential breakthrough in the treatment of PD and early clinical trials using AAV2-neurturin, a trophic factor that has shown the ability to protect dopaminergic degeneration in preclinical PD models, are underway.
|
23228025 |
2013 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study provides Class IV evidence that bilateral neurturin gene delivery (CERE-120) to the SN plus putamen in patients with moderately advanced PD is feasible and safe.
|
23576625 |
2013 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
This may be best exemplified by adeno-associated virus serotype-2-neurturin (CERE-120), a viral-vector construct designed to deliver the neurotrophic factor, neurturin to degenerating nigrostriatal neurons in Parkinson's disease.
|
22926166 |
2013 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent advances in PD research have demonstrated that gene delivery of trophic factors, glial cell line-derived neurotrophic factor (GDNF) and neurturin, in particular, can provide structural and functional recovery in rodent and nonhuman primate models of PD.
|
23390096 |
2013 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Conversion of human umbilical cord mesenchymal stem cells in Wharton's jelly to dopamine neurons mediated by the Lmx1a and neurturin in vitro: potential therapeutic application for Parkinson's disease in a rhesus monkey model.
|
23724014 |
2013 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
As alternative therapeutic strategies, the following four approaches are currently under evaluation for clinical gene therapy trials in PD; 1) recombinant adeno-associated virus 2 system encoding aromatic L-amino acid decarboxylase (AADC), 2) glutamic acid decarboxylase (GAD) and 3) Neurturin, and 4) equine infectious anemia virus-based lentiviral system encoding AADC, tyrosine hydroxylase (TH) and GTP cyclohydrolase I (GCH) in a single transcriptional unit.
|
22834832 |
2012 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Current gene therapy approaches for Parkinson's disease (PD) deliver neurotrophic factors like glial cell line-derived neurotrophic factor (GDNF) or neurturin via neuronal transgene expression.
|
22086235 |
2012 |
Parkinson Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
NRTN-expression was associated with occasional, sparse TH-induction in the striatum of PD, but nothing apparent in the SNc.
|
21322017 |
2011 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial.
|
20970382 |
2010 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Neurturin (NTN) and glial cell line-derived neurotrophic factor have potent neuroprotective and neurorestorative effects on dopaminergic neurons, but their use in treating Parkinson's disease has been limited by significant delivery obstacles.
|
19349823 |
2009 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this phase I, open-label clinical trial, 12 patients aged 35-75 years with a diagnosis of PD for at least 5 years in accordance with the UK Brain Bank Criteria received bilateral, stereotactic, intraputaminal injections of adeno-associated virus serotype 2-neurturin (CERE-120).
|
18387850 |
2008 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The mechanisms by which transgenic therapy treats PD might involve functional enhancement of residual dopaminergic neurons by NTN, which significantly reduces the number of rotations in animals, but not increase the numbers of existing dopaminergic neurons.
|
17336273 |
2007 |